Inhibition of nitric oxide synthase by nasal decongestants


ABSTRACT: The nasal decongestants oxymetazoline and xylometazoline are frequently used in the topical treatment of rhinitis and sinusitis. As nitric oxide (NO) is thought to play a role in inflammation of the upper respiratory tract, the aim of this study was to examine the in vitro effects of these compounds on the activity and the expression of NO producing enzymes, including the inducible form of NO synthase (iNOS) and the constitutive isoform of NO synthase (cNOS).

Experiments concerning the effects of both compounds on enzymatic activity and enzyme induction of iNOS were performed in a lipopolysaccharide (LPS) induced rat alveolar macrophage cell line (NR8383) using the Griess assay and the 3H-citrulline assay respectively. The effects on cNOS were examined in fresh rat synaptosomes using the 3H-citrulline assay. The direct scavenging properties of both compounds were investigated using an amperometric NO sensor.

Oxymetazoline and xylometazoline were shown to have a dose dependent inhibitory effect on total iNOS activity indicated by nitrite/nitrate formation in the Griess assay. This effect was found to be due to an inhibition of induction of the enzyme rather than inhibition of the enzyme itself, as was investigated in two separate experiments using the 3H-citrulline assay. Inhibition of cNOS was moderate and in the same order of magnitude as the inhibition of enzymatic iNOS activity. Direct scavenging of NO could not be detected.

As constitutive nitric oxide synthase activity is thought to serve beneficial physiological functions, and exaggerated inducible nitric oxide synthase activity may cause exacerbation of the inflammatory process, pharmacological treatment influencing the nitric oxide generating system should focus on inhibition of inducible nitric oxide synthase alone. The specific characteristics of these decongestants in vitro suggests suitability for this application and may indicate an additional beneficial effect in the treatment of upper respiratory tract inflammation.

indicate the involvement of NO in the pathogenesis of upper respiratory tract inflammation.

In upper airway inflammation, nasal decongestants such as oxymetazoline and xylometazoline, are frequently used in the topical treatment. Their effectiveness is thought to be due to direct \( \alpha \)-adrenergic receptor stimulation on the vascular smooth muscle in the nasal mucosa, leading to vasoconstriction. However, it is justified to presume that, in the clinically used concentrations, which are in the millimolar range, other molecular mechanisms play a role in the therapeutic effect. Recently the distinct antioxidant properties of oxymetazoline and xylometazoline i.e. hydroxyl radical scavenging and lipid peroxidation inhibition have been reported [19].

Presuming that the NO generating system is involved in the pathogenesis of upper respiratory tract inflammation, the effects of oxymetazoline and xylometazoline on activity and expression of cNOS and iNOS were determined in an in vitro model. In addition, possible NO scavenging properties were investigated.

**Materials and methods**

**Chemicals**

Roswell Park Memorial Institute (RPMI) 1640 medium, Ham's F-12 medium, glutamine and Fungibact were obtained from BioWhittaker (Walkersville, MD, USA). Foetal calf serum (FCS), N-2-hydroxyethylpiperazine-N-2-ethanesulphonic acid (HEPES), tris hydroxymethyl- amino methane (Tris) and ethylene diamine tetracetic acid (EDTA) were purchased from Life Technologies (Paisley, UK). Dowex was obtained from ACROS (Geel, Belgium). Leupeptin, phenylmethylsulfonyl fluoride (PMSF), dithiothreitol, aprotin, lipopolysaccharide (LPS), reduced nicotinamide adenine dinucleotide phosphate (NADPH), L-arginine, N-tris (hydroxymethyl)methyl-2-aminoethanesulphonic acid (TES), \( L \)-nitroarginine methyl ester (\( L \)-NAME), oxymetazoline, xylometazoline, \( N \)-(1-naphthyl)ethylenediamine, sulphanylamide and \( 8 \)-anilino-1-naphtalene-sulphonic acid were purchased from Sigma Chemicals Co. (St. Louis, MO, USA). Trypsin inhibitor from soybean was obtained from Difco Laboratories Inc. (Detroit, Michigan, USA). Sucrose and ethylene glycol tetra aetic acid (EGTA) were purchased from J.T. Baker (Deventer, Holland); [2,3,4,5]-\( 3H \)-arginine was obtained from Amersham International plc. (Little Chalfont, Buckinghamshire, UK). All other used chemicals were of reagent grade.

The macrophage cell line, NR8383 was kindly provided by R.J. Helmke, (Dept of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA). Klebsiella Pneumoniae were a kind gift from J. van Amsterdam (Rijksinstituut voor Volksgezondheid en Milieu, Bilthoven, the Netherlands).

**Study design**

To determine the effects of oxymetazoline and xylometazoline on iNOS and cNOS experiments according to the diagram shown in figure 1 were conducted. iNOS was expressed in rat alveolar macrophages by adding LPS in the presence of absence of the test compounds. Primarily the effects on total iNOS activity were measured by the formation of nitrate and nitrite, which was determined in the Griess-assay [20]. To elucidate the findings, a second set of experiments was performed using the \( 3H \)-citrulline assay [21], in which the conversion of tritiated \( L \)-arginine to \( L \)-citrulline is measured. By adding the test compounds only during LPS induction or only after LPS induction, effects on enzyme induction and enzymatic activity respectively could be separated. In addition the effects of the test compounds on constitutive nitric oxide synthase (cNOS) activity (\( 3H \)-citrulline assay) and nitric oxide (NO) scavenging (amperometric NO sensor method) were investigated.

**Cell culture and induction of nitric oxide synthase**

A rat pulmonary alveolar macrophage cell line, NR8383, was used as the source of iNOS [22, 23]. Cells were maintained in culture at a floating cell concentration of \( 10^5 \) cells.mL\(^{-1} \) in RPMI 1640 medium containing 2 mM glutamine, 0.5% Fungibact (50 U.mL\(^{-1} \) penicillin, 50 \( \mu \)g.mL\(^{-1} \) streptomycin) and 10% heat inactivated FCS. Cells were grown in 162-cm\(^2 \) flasks (Costar Cambridge, MA, USA) in a humidified, 37°C, 5% CO\(_2\) incubator. Cells were collected (112 \( \times \) g, 1000 revolutions per minute (rpm), Heraeus Labofuge 400R, 5 min, 25°C) and resuspended at an cell concentration of \( 10^6 \) cells.mL\(^{-1} \) in Ham's F-12 medium containing 2 mM glutamine and 0.5% Fungibact (50 U.mL\(^{-1} \) penicillin, 50 \( \mu \)g.mL\(^{-1} \) streptomycin). NOS was induced by addition of 10 \( \mu \)g bacterial LPS.mL\(^{-1} \) with or without the test compounds oxymetazoline and xylometazoline in different concentrations. The samples were incubated during 24 h (37°C, 5% CO\(_2\)). The known NOS inhibitor \( L \)-NAME was used as reference compound.
Reduction of nitrate to nitrite and determination of nitrite: the Griess-assay

In order to measure the effect of LPS on total nitrite/nitrate formation as well as the inhibition by 1-NAME, oxymetazoline and xylometazoline on the LPS effect, cells were incubated for 24 h with LPS and in the absence and presence of the test compounds in final concentrations varying between 10^{-9} M and 10^{-3} M. An aliquot of 150 μL of the cell suspension was deproteinated by adding 20 μL NaOH (1 M) and 20 μL ZnSO₄ (1 M). After shaking firmly the incubations were left on ice for 5 min and centrifuged (5 min, 1,500 × g at 4°C, Heraeus Christ, Biofuge A). For the conversion of nitrate to nitrite K. Pneumoniae (1.4 mg·ml⁻¹ in 50 mM PBS, pH=7.4) was mixed with 2 volumes of 0.2 M TES (pH=7.0) and 2 volumes of 0.5 M sodium formate. Of this mixture, 50 μL was added to 100 μL of the deproteinized sample. Nitrate reduction was performed at room temperature in a vacuum desiccator containing a dish of water to reduce evaporation of the reaction mixtures. After 30 min the tubes were removed and 0.5 ml of nitrogen flushed water was added. After centrifugation (4°C, 15,000 × g at 4°C) 0.5 mL of the incubate mixture was added to 50 μL of sulphanyl amide (1% in 5% H₃PO₄) and the tubes were placed at 4°C for 10 min. After this incubation 50 μL of 0.1% weight/volume (w/v) N-(1-naphthyl) ethylenediamine was added and within 30 min the absorption of nitrite was determined at 540 nm in a Packard Argus 400 microplate reader. Standards containing 0–150 μM NaN₃ and NaNO₃ were used for quantification.

Determination inhibition of nitric oxide synthase activity: ³H-citrulline assay

In order to separate the effects of the test compounds on induction of iNOS and on the enzymatic iNOS activity per se, two different sets of experiments were performed. To establish the effect of the test compounds on iNOS induction, a 24 h incubation of the N8383 cells with LPS was performed in the presence of test compounds. After the 24 h incubation period the test compounds were removed by washing. To establish the effect of the test compounds on iNOS enzymatic activity, cells were preincubated for 24 h with LPS in the absence of test compounds. These were only added during the conversion of l-arginine to l-citrulline in the ³H-citrulline assay.

After incubation with LPS, with or without test compounds (10⁻⁸ to 10⁻³ M), N8383 cells were collected and resuspended at a cell concentration of 10⁷ cell·ml⁻¹ in Tris/HCl-buffer (50 mM, pH=7.4 at 4°C) containing 2 μM leupeptin, 1 mM PMSF, 1 mM dithiothreitol, 10 μg·ml⁻¹ trypsin inhibitor from soybean, 2 μg·ml⁻¹ aprotinin, 0.1 mM EDTA and 230 mM sucrose. The cell suspension was subsequently sonicated for 5 min at 4°C. Of the obtained cell suspension 40 μL was added to 60 μL of a Tris HCl-buffer (50 mM, pH=7.4 at 37°C) containing 1 mM NADPH, 10 μM L-arginine and 20 nCi [³H] L-arginine (specific activity; 63 Ci·mmol⁻¹). For measuring the enzymatic inhibition test compounds were added in a concentration of 10⁻⁸ to 10⁻³ M. Activity of iNOS was measured in the presence of 1 mM EGTA, whereas cNOS activity was determined using 2 mM CaCl₂. Nonenzymatic conversion was determined by heating the cell suspension (100°C for 2 min). Both cNOS activity and nonenzymatic conversion were not found. The reaction was carried out for 45 min at 37°C and terminated by adding 1 ml of ice-cold Hepes-buffer (20 mM, pH=5.5 at 4°C) and putting the vials on ice. l-arginine was removed from the reaction mixture by adding 1 ml of the ion-exchanger Dowex (H₂O/Dowex-50W, 1:1, Na⁺-form, 200–400 mesh, 8% crosslinks, pH=7.0) and shaking firmly. After centrifugation (15 min, 2,100 × g at 4°C) the reaction product [³H] l-citrulline was measured by transferring 1 ml of the supernatant to scintillation vials containing 4 ml Packard Ultima Gold scintillation fluid. Radioactivity was counted in a Packard Tri-carb (1900 CA) liquid scintillation analyzer. All samples were corrected for background radioactivity.

The same ³H-citrulline assay was used to determine the possible inhibitory effects of oxymetazoline and xylometazoline (concentrations between 10⁻⁷ M–3×10⁻⁵ M) on cNOS activity. In these experiments enzymatic activity was measured in the presence of 2 mM CaCl₂. l-NAME was used as reference compound. However, these measurements were performed in synaptosomes obtained from the cerebella of male Wistar rats as these cells are known to contain high levels of cNOS. Activity of iNOS could not be detected in this tissue as was shown by using a calcium free buffer.

Determination of cell viability

In the experiments in which the alveolar cell line, NR 8383, was used, the viability of the cells was tested at different stages of the experiments using thrypan blue. When more than 5% of the cells in a sample were stained with thrypan blue the samples was no longer viable and therefore disregarded.

Determination of nitric oxide scavenging

Possible NO-scavenging properties of both compounds were investigated by using a amperometric NO-sensor [24]. As a reference compound the well known NO scavenger haemoglobin was used. Two microlitres of NO-spiked deoxygenated water was added to 20 μL of 50 mM phosphate buffer (pH=7.4) in a thermostated vessel (37°C). The vessel was kept under a N₂ atmosphere. The decrease in NO concentration with time was measured with an Iso-NO meter (World Precision instruments, Sarasota FL, USA) coupled to both a MacLab™ interface (ML020 MacLab/8, AdInstruments, London, UK) and an Apple Macintosh computer with "Chart" software and a chart recorder (Kipp, Delft, the Netherlands) in the presence and absence of the test compounds oxymetazoline and xylometazoline (final concentrations up to 10⁻³ M) and reference compound (final concentrations used were 3.9 × 10⁻⁵ and 7.8 × 10⁻⁶) in solution. During this procedure the reaction mixture was mixed using a magnetic stirrer.
Results

Determination of inhibition of inducible nitric oxide synthase activity

Nitrite formation after lipopolysaccharide stimulation. The effects of L-NAME, oxymetazoline and xylometazoline on the production of nitrite and nitrate, which are formed after oxidation of the unstable NO, were determined in the Griess-assay. The amount of nitrite measured after nitrate reduction, reflects the iNOS activity.

Nitrite formation could only be measured in LPS induced cells. When no test compound was added the LPS induced cells gave a mean total nitrite concentration of 117±12 μM. All data concerning iNOS are presented as the fraction of this value.

All compounds showed a dose dependent inhibitory effect on the nitrite formation (fig. 2). In contrast to L-NAME, oxymetazoline and xylometazoline showed no inhibition of nitrite formation up to a concentration of 10^{-4} M, whereas at this concentration L-NAME gave 25% inhibition. However, oxymetazoline and xylometazoline inhibited the nitrite formation completely at a concentration of 1 mM whereas L-NAME only inhibited ~60%. To exclude possible inhibition of cell growth or reaction with components of the Griess-assay by the compounds, control experiments were performed. None of these confounding reactions occurred.

Citrlulline formation after lipopolysaccharide stimulation in the presence of test compounds

To elucidate the mode of action of this inhibitory effect, the compounds were investigated in the 3H-citrulline assay in which the effect of the compounds on iNOS induction and enzymatic iNOS activity could be separated. L-citrulline is formed from L-arginine by NOS under the production of NO. The amount of L-citrulline production reflects the enzymatic activity of NOS.

When cells were not stimulated with LPS, no L-citrulline could be detected. The baseline radioactivity value of the formed 3H-citrulline was determined in LPS induced cells to which no test compound was added. The inhibition by the test compounds is presented as a fraction of the LPS induced value.

Different concentrations of L-NAME, oxymetazoline and xylometazoline were present during LPS induced iNOS induction for 24 h and then removed by washing. Oxymetazoline and xylometazoline showed a prominent dose dependent reduction of L-citrulline formation (fig. 3). More than 50% inhibition of L-citrulline formation was obtained for both compounds at a concentration of 0.3 mM, whereas complete inhibition for both compounds was obtained at 1 mM. L-NAME also showed some reduction however, at a concentration of 1 mM only 50% reduction was found.

Citrlulline formation after lipopolysaccharide stimulation in the absence of test compounds: inhibition of enzymatic inducible nitric oxide synthase activity

When cells were not stimulated with LPS, L-citrulline could not be detected. The baseline radioactivity value of the formed 3H-citrulline was determined in LPS induced cells to which no test compound was added. The inhibition by the test compounds is presented as a fraction of the LPS induced value.

Oxymetazoline and xylometazoline showed a moderate concentration dependent inhibitory effect on the LPS stimulated iNOS activity (fig. 4). At a concentration of 1 mM, added after 24 h of LPS stimulation, both compounds inhibited iNOS activity ~50%, whereas L-NAME inhibited almost completely (85%) even when used at a concentration 10 times lower. The test compounds did not influence the separation of 3H-citrulline and 3H-arginine.
Determination of the inhibition of constitutive nitric oxide synthase

The baseline radioactivity value of the formed \(^{3}\text{H}\)-citrulline was determined in samples to which no test compound was added. The data are presented as fractions of the absolute baseline values.

The inhibition of cNOS activity in rat brain tissue by oxymetazoline and xylometazoline was concentration dependent and in the same order of magnitude as inhibition of enzymatic iNOS activity measured by the \(^{3}\text{H}\)-citrulline assay. At a concentration of 1 mM oxymetazoline and xylometazoline inhibited l-citrulline formation by 50% and 65% respectively (fig. 5). The inhibition activity of l-NAME, was as expected, much more prominent. At a concentration of 0.3 mM already 50% of cNOS activity was inhibited (data not shown).

Determination of nitric oxide radical scavenging

In contrast to the reference haemoglobin, which showed potent scavenging, no scavenging of NO radicals occurred by either oxymetazoline or xylometazoline added to the reaction mixture at final concentrations up to \(10^{-3}\) M.

Discussion

The effects of the nasal decongestants oxymetazoline and xylometazoline on the induction and activity of iNOS and the activity of eNOS were investigated. NOS activity is of importance in inflammatory disorders of the upper respiratory tract via at least two mechanisms. Firstly the regulation of nasal vascular tone is thought to be under eNOS control [14, 16, 25] and secondly iNOS is important in the modulation of the inflammatory and immunological response [18]. As high doses of oxymetazoline and xylo-

metazoline are frequently used in the topical treatment of upper respiratory tract inflammation, the effect of these compounds on NO regulation is of interest.

LPS was used to induce iNOS in a macrophage cell line. The false substrate for NOS, l-NAME, as measured by the nitrite/nitrate formation, decreased the amount of NO metabolites dose dependently, although not completely. Since oxymetazoline and xylometazoline in the same concentration were capable of complete inhibition of iNOS, this finding suggests at least an additional mode of pharmacological action of these compounds. It should be noted that in the nitrite/nitrate experiments NO was formed as an intermediate and that the inhibitory effects on NOS could be due to scavenging of NO by the used test compounds. To exclude this, the test compounds were investigated for possible NO scavenging properties. No NO scavenging occurred.

Decreased NO formation could be explained by either, the inhibition of enzymatic activity or the inhibition of induction, hence these were investigated separately. Oxymetazoline and xylometazoline were not full inhibitors of both iNOS and cNOS activity, measured by \(^{3}\text{H}\)-citrulline formation. This is in contrast to l-NAME, which showed complete enzymatic inhibition of NOS, which is in accordance with the literature [26]. It is suggested that the incomplete enzymatic inhibition of both iNOS and cNOS by oxymetazoline and xylometazoline may be due to binding of the imidazole part of these compounds to the haem domain of NOS. This mode of action is comparable but less efficient than for arginine derivatives such as l-NAME [27]. In this way it was proven that the inhibitory effect of oxymetazoline and xylometazoline could not be fully explained by enzyme inhibition. Inhibition of induction of the iNOS enzyme might therefore be involved as well. This was investigated in an experiment in which iNOS enzyme activity was measured after washing away the test compounds, i.e. the test compounds were present during LPS induction of iNOS. Both compounds, in

---

Fig. 4. – The inhibitory effect of oxymetazoline (■) and xylo-
metazoline (□) on the enzymatic inducible nitric oxide synthase (iNOS) activity measured by formation of l-citrulline using the \(^{3}\text{H}\)-citrulline assay. l-nitroarginine methy ester (l-NAME) (●) was used as reference compound. Compounds were only added to the reaction mixture during incubation with l-arginine. A moderate concentration dependent reduction in l-citrulline formation was seen for oxymetazoline and xylometazoline. In contrast to l-NAME, which gave prominent inhibition of enzymatic iNOS activity at a concentration of \(10^{-7}\), oxymetazoline and xylometazoline inhibited l-citrulline formation ~50% at a concentration of \(10^{-3}\) M.

Fig. 5. – The inhibitory effect of oxymetazoline (■) and xylo-
metazoline (□) on the enzymatic activity of constitutive nitric oxide synthase (cNOS) measuring l-citrulline formation using the \(^{3}\text{H}\)-citrulline assay. The l-citrulline production was concentration dependent diminished by both compounds. At a concentration of \(10^{-3}\) M oxymetazoline inhibited cNOS by 50% and xylometazoline by 65%. The effects of both compounds on the enzymatic activity of cNOS are comparable to their effects on the enzymatic activity of inducible nitric oxide synthase.
contrast to L-NAME, completely inhibited spontaneous iNOS activity and thus expression of iNOS.

It is known that the induction of iNOS is regulated by transcription factors, of which the most important is nuclear factor-kB (NF-kB) [28]. As NF-kB in cells is activated by many factors such as micro-organisms, oxidants, antigens and LPS [29] a possible site of action of oxymetazoline and xylometazoline may be the inhibition of the activation of NF-kB. The nasal mucosa has an important function in preparing the inspired air before entering the lungs through filtering particles and regulating humidity and temperature. NO seems to play a pivotal role in these physiological functions as amongst others it has been shown that NO is involved in the regulation of the vascular tone in the nasal mucosa [25, 30]. By this means NO is thought to modulate nasal vascular conductance and nasal cavity volume, which are correlated to the nasal airway resistance [16, 17]. It should be noted however, that recent investigations, using high flow rate insufflation, contradict the existence of such a relationship [31, 32]. The difference in these results is thought to be due to underestimation of measured NO outputs as low flows were used instead of higher and probably more physiological transnasal airflows [33]. Another possibility is that this discrepancy might be explained by the fact that NO levels measured in nasal air, which are predominantly produced by a Ca²⁺-independent form of NOS in epithelial cells in the paranasal sinuses [34, 35] are not responsible for vascular tone regulation, which may be predominantly under control of nasal vascular epithelial cNOS. This speculation might be supported by the finding that lidocain showed strong inhibition of sinus NO production in contrast to nasal NO production [36].

Furthermore, it has been shown that human nasal mast cells, next to alpha adrenoceptor effects, play a major role in the regulation of the blood supply to the nasal mucosa. They contain a particulate isoform of NOS, which besides other vasoactive substances, may effect the congestive state of the nasal mucosa [37]. In addition, nasal exudation, of importance in nasal inflammation, also seems to be mediated by NO via increase of the vascular permeability [38]. NO, generated via iNOS, which is induced in inflammatory cells and epithelium of the upper respiratory tract, is an important mediator in modulating the inflammatory and immunological response [18, 39]. Involvement of NO was shown for rhinitis based on house dust mite allergy [13], seasonal rhinitis [11], chronic rhinitis [15] and nasal polyps [14]. NO levels are high in exhaled air, which was shown to be originating mainly from the nasal and paranasal airways [34, 40–42]. These high concentrations of the reactive NO may contribute to aggravating airway inflammation, which has been shown after, for example, viral airway infection [43]. The involvement of iNOS may be supported by the finding that glucocorticoids, which amongst others inhibit the induction of iNOS and have beneficial effects in treating airway inflammation, inhibit the increase in exhaled NO in asthmatic patients [44].

All of the previously mentioned studies indicate that NO has a role in upper respiratory tract inflammation. This role may be influenced by nasal decongestants like oxymetazoline and xylometazoline. Although, the role of nasal NO in nasal vascular regulation is not clearly established most studies support the observation that administration of nasal decongestants significantly decreases nasal NO concentration [30, 31]. The mechanism by which decongestants reduce NO concentration is not known. It was speculated to be due to vasoconstriction of the nasal venous sinuwoids, which may lead to a decreased epithelial surface area and affect the NO diffusion into the lumen of the nasal cavity [45]. It may also be related to the reduction of bloodflow leading to a diminished availability of substrates for NOS or by a toxic effect of the decongestant in the chain of reactions that produces NO [31]. Until now a specific site of action could not be ascertained.

In the present study this mode of action was elucidated as a direct inhibitory effect on enzymatic activity of cNOS and iNOS, but especially induction of iNOS was shown. In addition, no direct scavenging effect of either compound could be found.

The results were obtained in rat alveolar macrophages as these cell lines are a reliable source of iNOS [22, 23]. Differences in the NOS systems have been found between cell types of animals of different species and humans [9]. Therefore, the results cannot be directly extrapolated to human upper airways. However, although this is an in vitro model the results may contribute to the understanding of NO in upper respiratory tract pathophysiology and the influence of nasal decongestants herein. Presuming that the NO generating system plays a role in the pathogenesis of upper respiratory tract inflammations, the findings may suggest an additional beneficial effect of the nasal decongestants oxymetazoline and xylometazoline in the topical treatment of these disorders. It should be noted, however, that these compounds, at least in their pharmaceutical matrix, also have unfavourable effects on nasal mucosa like decreasing mucociliary clearance [46, 47], and inducing rhinitis medicamentosa [48].

In conclusion, the studies mentioned above imply that constitutive nitric oxide synthase activity serves beneficial physiological functions in the nose, whereas an exaggerated inducible nitric oxide synthase activity, which is induced by overexpression, causes an exacerbation of the
inflammatory process. Possible treatment via nitric oxide mechanisms should therefore primarily focus on inhibition of inducible nitric oxide synthase alone, leaving the necessary physiological control via constitutive nitric oxide synthase intact. In an in vitro model oxymetazoline and xylometazoline showed only moderate effects as direct inhibitors of the nitric oxide-producing enzymes. However, these compounds, used in their clinically applied concentration, are able to inhibit the induction of inducible nitric oxide synthase completely, which renders them selective tools for attenuation of inducible nitric oxide synthase activity, a mode of action which has not been described before.

References

34. Lundberg JON, Farkas-Szallasi T, Weitzberg E, et al.


